Showing results (261-270 of 336) with videos related to
Sort By:
Pageof 34
Cancer|July 1, 1993
Single-agent carboplatinum for advanced seminoma. A phase II studyH J Schmoll, A Harstrick, C Bokemeyer, et al.Cancer Chemotherapy and Pharmacology|January 1, 1993
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adultsA Harstrick, C Bokemeyer, H J Schmoll, et al.Chirurgie (Heidelberg, Germany)|December 13, 2022
[The COVID-19 pandemic had significant impact on duration of surgery and hospitalization time for patients after cholecystectomy]L Fischer, T Iber, M Feißt, et al.Archives of Gynecology and Obstetrics|July 31, 2025
The implementation of frailty assessment in gynecologic oncology: an international multicenter JAGO-NOGGO surveyC Flethe, C Krause, A von Beckerath, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysisC Bokemeyer, C Kollmannsberger, C Meisner, et al.Anticancer Research|March 28, 2001
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamideJ T Hartmann, L M Fels, A Franzke, et al.World Journal of Urology|June 29, 2004
Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experienceM A Kuczyk, C Bokemeyer, C Kollmannsberger, et al.Seminars in Oncology|April 1, 1992
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trialH J Schmoll, C H Köhne-Wömpner, W Hiddemann, et al.Investigational New Drugs|August 13, 2008
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)G Schilling, M Bruweleit, N Harbeck, et al.European Journal of Cancer (Oxford, England : 1990)|May 5, 2015
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancerC Bokemeyer, C-H Köhne, F Ciardiello, et al.Pageof 34